Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
Relapsed/Refractory Multiple Myeloma
BIOLOGICAL: Adult differentiated autologous T-cells with anti-BCMA specificity
Overall response rate (ORR), 3 months|Cytokine release syndrome rate, within 30 days of first infusion
Duration of the response, up to 36 months after treatment|Response rate, over the first year|Complete response rate (CR), at month 3 and month 6 of first infusion|Overall response rate (ORR), at month 6 of first infusion|Time to complete response, up to 36 months after treatment|Response rate of extramedullary disease by PET-CT, up to 36 months after treatment|Negative MRD rate in bone marrow, at month 3 and month 6 of first infusion|Response rate of extramedullary disease by PET-TC, at month 3|Progression free survival (PFS), at month 12, and up to 36 months after treatment|Overall survival (OS) defined as the time elapsed between the infusion of ARI0002h and the death of the patient from any cause, up to 36 months after treatment|Presence of tumor lysis syndrome, up to 36 months after treatment|Presence of cytokine release syndrome, up to 36 months after treatment|Presence of neurological toxicity, up to 36 months after treatment|Presence of prolonged cytopenia, up to 36 months after treatment|Persistence of CART BCMA ARI0002 in peripheral blood, month 1, 2, 3, 4, 5, 6 and every 6 months until 2 years of follow up|Expression of BCMA, at screening, at day +28, at day +100, at month 6, 12, 18 and 24|Levels of soluble BCMA in serum, at screening, at day 0, +3, +7,+14,+28, +70 +100, at month 4, 5, 6, 7, 8, 9, 1,11, 12, 18 and 24
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.